-
1
-
-
34548072307
-
N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency
-
Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA., (2007). N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7:355–9
-
(2007)
Curr Opin Pharmacol
, vol.7
, pp. 355-359
-
-
Atkuri, K.R.1
Mantovani, J.J.2
Herzenberg, L.A.3
Herzenberg, L.A.4
-
3
-
-
0345018815
-
N-acetylcysteine: pharmacological considerations and experimental and clinical applications
-
Cotgreave IA., (1997). N-acetylcysteine:pharmacological considerations and experimental and clinical applications. Adv Pharmacol 38:205–27
-
(1997)
Adv Pharmacol
, vol.38
, pp. 205-227
-
-
Cotgreave, I.A.1
-
4
-
-
57649148545
-
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
-
Dodd S, Dean O, Copolov DL, et al. (2008). N-acetylcysteine for antioxidant therapy:pharmacology and clinical utility. Expert Opin Biol Ther 8:1955–62
-
(2008)
Expert Opin Biol Ther
, vol.8
, pp. 1955-1962
-
-
Dodd, S.1
Dean, O.2
Copolov, D.L.3
-
5
-
-
84925699316
-
The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat
-
Donovan MD, O'brien FE, Boylan GB, et al. (2015). The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain:an integrated in vivo microdialysis study in the rat. J Pharm Pharmacol 67:501–10
-
(2015)
J Pharm Pharmacol
, vol.67
, pp. 501-510
-
-
Donovan, M.D.1
O'brien, F.E.2
Boylan, G.B.3
-
6
-
-
33645743694
-
The human organic anion transporter 3 (oat3; slc22a8): genetic variation and functional genomics
-
Erdman AR, Mangravite LM, Urban TJ, et al. (2006). The human organic anion transporter 3 (oat3; slc22a8):genetic variation and functional genomics. Am J Physiol Renal Physiol 290:F905–12
-
(2006)
Am J Physiol Renal Physiol
, vol.290
, pp. F905-F912
-
-
Erdman, A.R.1
Mangravite, L.M.2
Urban, T.J.3
-
7
-
-
84865651194
-
Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant n-acetylcysteine
-
Erickson MA, Hansen K, Banks WA., (2012). Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier:protection by the antioxidant n-acetylcysteine. Brain Behav Immun 26:1085–94
-
(2012)
Brain Behav Immun
, vol.26
, pp. 1085-1094
-
-
Erickson, M.A.1
Hansen, K.2
Banks, W.A.3
-
8
-
-
0037342554
-
The antioxidants alpha-lipoic acid and n-acetylcysteine reverse memory impairment and brain oxidative stress in aged samp8 mice
-
Farr SA, Poon HF, Dogrukol-Ak D, et al. (2003). The antioxidants alpha-lipoic acid and n-acetylcysteine reverse memory impairment and brain oxidative stress in aged samp8 mice. J Neurochem 84:1173–83
-
(2003)
J Neurochem
, vol.84
, pp. 1173-1183
-
-
Farr, S.A.1
Poon, H.F.2
Dogrukol-Ak, D.3
-
9
-
-
84868475995
-
N-acetylcysteine ethyl ester (nacet): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential
-
Giustarini D, Milzani A, Dalle-Donne I, et al. (2012). N-acetylcysteine ethyl ester (nacet):a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochem Pharmacol 84:1522–33
-
(2012)
Biochem Pharmacol
, vol.84
, pp. 1522-1533
-
-
Giustarini, D.1
Milzani, A.2
Dalle-Donne, I.3
-
10
-
-
0034023927
-
Efficacy of oral long-term n-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials
-
Grandjean EM, Berthet P, Ruffmann R, Leuenberger P., (2000). Efficacy of oral long-term n-acetylcysteine in chronic bronchopulmonary disease:a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22:209–21
-
(2000)
Clin Ther
, vol.22
, pp. 209-221
-
-
Grandjean, E.M.1
Berthet, P.2
Ruffmann, R.3
Leuenberger, P.4
-
11
-
-
0035869559
-
Determination of reduced, protein-unbound, and total concentrations of n-acetyl-l-cysteine and l-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography
-
Harada D, Naito S, Kawauchi Y, et al. (2001). Determination of reduced, protein-unbound, and total concentrations of n-acetyl-l-cysteine and l-cysteine in rat plasma by postcolumn ligand substitution high-performance liquid chromatography. Anal Biochem 290:251–9
-
(2001)
Anal Biochem
, vol.290
, pp. 251-259
-
-
Harada, D.1
Naito, S.2
Kawauchi, Y.3
-
12
-
-
84872814431
-
Amelioration of acute sequelae of blast induced mild traumatic brain injury by n-acetyl cysteine: a double-blind, placebo controlled study
-
Hoffer ME, Balaban C, Slade MD, et al. (2013). Amelioration of acute sequelae of blast induced mild traumatic brain injury by n-acetyl cysteine:a double-blind, placebo controlled study. PLoS One 8:e54163
-
(2013)
PLoS One
, vol.8
, pp. 54163
-
-
Hoffer, M.E.1
Balaban, C.2
Slade, M.D.3
-
13
-
-
0014145811
-
Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine
-
Hurst GA, Shaw PB, LeMaistre CA., (1967). Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine. Am Rev Respir Dis 96:962–70
-
(1967)
Am Rev Respir Dis
, vol.96
, pp. 962-970
-
-
Hurst, G.A.1
Shaw, P.B.2
LeMaistre, C.A.3
-
14
-
-
84879415192
-
Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position
-
Kalvass JC, Polli JW, Bourdet DL, et al. (2013). Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely:the ITC evidence-based position. Clin Pharmacol Ther 94:80–94
-
(2013)
Clin Pharmacol Ther
, vol.94
, pp. 80-94
-
-
Kalvass, J.C.1
Polli, J.W.2
Bourdet, D.L.3
-
15
-
-
0038274495
-
Contribution of organic anion transporter 3 (slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier
-
Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y., (2003). Contribution of organic anion transporter 3 (slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 306:51–8
-
(2003)
J Pharmacol Exp Ther
, vol.306
, pp. 51-58
-
-
Kikuchi, R.1
Kusuhara, H.2
Sugiyama, D.3
Sugiyama, Y.4
-
16
-
-
0036784093
-
Identification of a mechanism by which the methylmercury antidotes n-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion: transport by the renal organic anion transporter-1
-
Koh AS, Simmons-Willis TA, Pritchard JB, et al. (2002). Identification of a mechanism by which the methylmercury antidotes n-acetylcysteine and dimercaptopropanesulfonate enhance urinary metal excretion:transport by the renal organic anion transporter-1. Mol Pharmacol 62:921–6
-
(2002)
Mol Pharmacol
, vol.62
, pp. 921-926
-
-
Koh, A.S.1
Simmons-Willis, T.A.2
Pritchard, J.B.3
-
17
-
-
12344261030
-
Active efflux across the blood-brain barrier: role of the solute carrier family
-
Kusuhara H, Sugiyama Y., (2005). Active efflux across the blood-brain barrier:role of the solute carrier family. NeuroRx 2:73–85
-
(2005)
NeuroRx
, vol.2
, pp. 73-85
-
-
Kusuhara, H.1
Sugiyama, Y.2
-
18
-
-
0020325272
-
Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans
-
Laskin OL, de Miranda P, King DH, et al. (1982). Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 21:804–7
-
(1982)
Antimicrob Agents Chemother
, vol.21
, pp. 804-807
-
-
Laskin, O.L.1
de Miranda, P.2
King, D.H.3
-
19
-
-
22744440362
-
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
-
Löscher W, Potschka H., (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology 76:22–76
-
(2005)
Progress in Neurobiology
, vol.76
, pp. 22-76
-
-
Löscher, W.1
Potschka, H.2
-
20
-
-
84900557627
-
Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (oat) 1 and oat3 in humans
-
Maeda K, Tian Y, Fujita T, et al. (2014). Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (oat) 1 and oat3 in humans. Eur J Pharm Sci 59:94–103
-
(2014)
Eur J Pharm Sci
, vol.59
, pp. 94-103
-
-
Maeda, K.1
Tian, Y.2
Fujita, T.3
-
21
-
-
84952949019
-
Combination therapies for traumatic brain injury: retrospective considerations
-
Margulies S, Anderson G, Atif F, et al. (2016). Combination therapies for traumatic brain injury:retrospective considerations. J Neurotrauma 33:101–12
-
(2016)
J Neurotrauma
, vol.33
, pp. 101-112
-
-
Margulies, S.1
Anderson, G.2
Atif, F.3
-
22
-
-
0029154990
-
Uptake and distribution of n-acetylcysteine in mice: tissue-specific effects on glutathione concentrations
-
McLellan LI, Lewis AD, Hall DJ, et al. (1995). Uptake and distribution of n-acetylcysteine in mice:tissue-specific effects on glutathione concentrations. Carcinogenesis 16:2099–106
-
(1995)
Carcinogenesis
, vol.16
, pp. 2099-2106
-
-
McLellan, L.I.1
Lewis, A.D.2
Hall, D.J.3
-
23
-
-
47949121279
-
Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats
-
Minematsu T, Hashimoto T, Aoki T, et al. (2008). Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. Drug Metab Dispos 36:1496–504
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 1496-1504
-
-
Minematsu, T.1
Hashimoto, T.2
Aoki, T.3
-
24
-
-
0035503798
-
Therapeutic efficacy of aortic administration of n-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
-
Neuwelt EA, Pagel MA, Hasler BP, et al. (2001). Therapeutic efficacy of aortic administration of n-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61:7868–74
-
(2001)
Cancer Res
, vol.61
, pp. 7868-7874
-
-
Neuwelt, E.A.1
Pagel, M.A.2
Hasler, B.P.3
-
25
-
-
2642579050
-
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis
-
Offen D, Gilgun-Sherki Y, Barhum Y, et al. (2004). A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 89:1241–51
-
(2004)
J Neurochem
, vol.89
, pp. 1241-1251
-
-
Offen, D.1
Gilgun-Sherki, Y.2
Barhum, Y.3
-
26
-
-
0023835113
-
Pharmacokinetics and bioavailability of reduced and oxidized n-acetylcysteine
-
Olsson B, Johansson M, Gabrielsson J, Bolme P., (1988). Pharmacokinetics and bioavailability of reduced and oxidized n-acetylcysteine. Eur J Clin Pharmacol 34:77–82
-
(1988)
Eur J Clin Pharmacol
, vol.34
, pp. 77-82
-
-
Olsson, B.1
Johansson, M.2
Gabrielsson, J.3
Bolme, P.4
-
27
-
-
0034753085
-
Mercapturic acids (n-acetylcysteine s-conjugates) as endogenous substrates for the renal organic anion transporter-1
-
Pombrio JM, Giangreco A, Li L, et al. (2001). Mercapturic acids (n-acetylcysteine s-conjugates) as endogenous substrates for the renal organic anion transporter-1. Mol Pharmacol 60:1091–9
-
(2001)
Mol Pharmacol
, vol.60
, pp. 1091-1099
-
-
Pombrio, J.M.1
Giangreco, A.2
Li, L.3
-
28
-
-
0018651356
-
Intravenous n-acetylcystine: the treatment of choice for paracetamol poisoning
-
Prescott LF, Illingworth RN, Critchley JA, et al. (1979). Intravenous n-acetylcystine:the treatment of choice for paracetamol poisoning. Br Med J 2:1097–100
-
(1979)
Br Med J
, vol.2
, pp. 1097-1100
-
-
Prescott, L.F.1
Illingworth, R.N.2
Critchley, J.A.3
-
29
-
-
84891883913
-
Existing and potential therapeutic uses for n-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits
-
Rushworth GF, Megson IL., (2014). Existing and potential therapeutic uses for n-acetylcysteine:the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 141:150–9
-
(2014)
Pharmacol Ther
, vol.141
, pp. 150-159
-
-
Rushworth, G.F.1
Megson, I.L.2
-
30
-
-
84877828545
-
The chemistry and biological activities of n-acetylcysteine
-
Samuni Y, Goldstein S, Dean OM, Berk M., (2013). The chemistry and biological activities of n-acetylcysteine. Biochim Biophys Acta 1830:4117–29
-
(2013)
Biochim Biophys Acta
, vol.1830
, pp. 4117-4129
-
-
Samuni, Y.1
Goldstein, S.2
Dean, O.M.3
Berk, M.4
-
31
-
-
0024991044
-
Modeling the enhanced uptake of zidovudine (azt) into cerebrospinal fluid. 1. Effect of probenecid
-
Sawchuk RJ, Hedaya MA., (1990). Modeling the enhanced uptake of zidovudine (azt) into cerebrospinal fluid. 1. Effect of probenecid. Pharm Res 7:332–8
-
(1990)
Pharm Res
, vol.7
, pp. 332-338
-
-
Sawchuk, R.J.1
Hedaya, M.A.2
-
32
-
-
24944482460
-
Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans
-
Shimizu M, Fuse K, Okudaira K, et al. (2005). Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metabo Dispos 33:1477–81
-
(2005)
Drug Metabo Dispos
, vol.33
, pp. 1477-1481
-
-
Shimizu, M.1
Fuse, K.2
Okudaira, K.3
-
33
-
-
84868661468
-
Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin e(2) produced in the brain
-
Tachikawa M, Ozeki G, Higuchi T, et al. (2012). Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin e(2) produced in the brain. J Neurochem 123:750–60
-
(2012)
J Neurochem
, vol.123
, pp. 750-760
-
-
Tachikawa, M.1
Ozeki, G.2
Higuchi, T.3
-
34
-
-
33645798634
-
Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid
-
Tahara H, Kusuhara H, Maeda K, et al. (2006). Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743–7
-
(2006)
. Drug Metab Dispos
, vol.34
, pp. 743-747
-
-
Tahara, H.1
Kusuhara, H.2
Maeda, K.3
-
35
-
-
0029642277
-
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP)
-
Versantvoort CHM, Bagrij T, Wright KA, Twentyman PR., (1995). On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer 63:855–62
-
(1995)
Int J Cancer
, vol.63
, pp. 855-862
-
-
Versantvoort, C.H.M.1
Bagrij, T.2
Wright, K.A.3
Twentyman, P.R.4
-
36
-
-
0027769788
-
Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis
-
Wong SL, Van Belle K, Sawchuk RJ., (1993). Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit:investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 264:899–909
-
(1993)
J Pharmacol Exp Ther
, vol.264
, pp. 899-909
-
-
Wong, S.L.1
Van Belle, K.2
Sawchuk, R.J.3
-
37
-
-
84947044454
-
Intravenous administration of stable-labeled n-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status
-
Zhou J, Coles LD, Kartha RV, et al. (2015). Intravenous administration of stable-labeled n-acetylcysteine demonstrates an indirect mechanism for boosting glutathione and improving redox status. J Pharm Sci 104:2619–26
-
(2015)
J Pharm Sci
, vol.104
, pp. 2619-2626
-
-
Zhou, J.1
Coles, L.D.2
Kartha, R.V.3
|